See more : Oi Wah Pawnshop Credit Holdings Limited (1319.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Great Novel Therapeutics Biotech & Medicals (7427.TWO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Great Novel Therapeutics Biotech & Medicals, a leading company in the Biotechnology industry within the Healthcare sector.
- Burley Minerals Ltd (BUR.AX) Income Statement Analysis – Financial Results
- Windlas Biotech Limited (WINDLAS.BO) Income Statement Analysis – Financial Results
- Beijing Kingfore HV & Energy Conservation Technology Co.,Ltd. (001210.SZ) Income Statement Analysis – Financial Results
- Niitaka Co., Ltd. (4465.T) Income Statement Analysis – Financial Results
- Ador Multiproducts Limited (ADORMUL.BO) Income Statement Analysis – Financial Results
Great Novel Therapeutics Biotech & Medicals (7427.TWO)
About Great Novel Therapeutics Biotech & Medicals
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei City, Taiwan.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Revenue | 4.85M | 540.00K | 630.00K | 0.00 | 0.00 |
| Cost of Revenue | 2.24M | 76.00K | 347.00K | 0.00 | 0.00 |
| Gross Profit | 2.62M | 464.00K | 283.00K | 0.00 | 0.00 |
| Gross Profit Ratio | 53.92% | 85.93% | 44.92% | 0.00% | 0.00% |
| Research & Development | 53.13M | 38.53M | 19.11M | 19.47M | 0.00 |
| General & Administrative | 17.50M | 19.37M | 17.70M | 10.42M | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 17.50M | 19.37M | 17.70M | 10.42M | 0.00 |
| Other Expenses | -729.00K | 723.00K | 149.00K | -1.39M | 0.00 |
| Operating Expenses | 2.62M | 57.90M | 36.80M | 29.89M | 0.00 |
| Cost & Expenses | 70.67M | 57.98M | 37.15M | 29.89M | 0.00 |
| Interest Income | 5.33M | 936.00K | 515.00K | 32.00K | 132.00K |
| Interest Expense | 91.00K | 0.00 | 0.00 | 21.00K | 0.00 |
| Depreciation & Amortization | 6.53M | 1.82M | 1.50M | 1.04M | 0.00 |
| EBITDA | -54.92M | -53.96M | -35.08M | -30.21M | -28.89M |
| EBITDA Ratio | -1,132.27% | -9,992.04% | -5,559.05% | 0.00% | 0.00% |
| Operating Income | -65.82M | -55.78M | -36.52M | -31.24M | 0.00 |
| Operating Income Ratio | -1,357.11% | -10,329.44% | -5,796.98% | 0.00% | 0.00% |
| Total Other Income/Expenses | 4.28M | 1.66M | 664.00K | -1.38M | 582.00K |
| Income Before Tax | -61.54M | -55.78M | -35.86M | -31.27M | 0.00 |
| Income Before Tax Ratio | -1,268.87% | -10,329.44% | -5,691.59% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -61.54M | -55.78M | -35.86M | -31.27M | 0.00 |
| Net Income Ratio | -1,268.87% | -10,329.44% | -5,691.59% | 0.00% | 0.00% |
| EPS | -1.70 | -2.31 | -1.70 | -1.97 | -2.20 |
| EPS Diluted | -1.70 | -2.31 | -1.70 | -1.97 | -2.20 |
| Weighted Avg Shares Out | 36.28M | 24.15M | 21.09M | 15.84M | 13.56M |
| Weighted Avg Shares Out (Dil) | 36.28M | 24.15M | 21.09M | 15.84M | 13.56M |
Source: https://incomestatements.info
Category: Stock Reports